Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory
bowel disease (IBD) is an important cause of loss of response to therapy that may lead to
escalation of dose or discontinuation of therapy. Antibodies may develop to infliximab (ATI)
or to adalimumab (ATA) and cause this loss of response, also known as a secondary loss of
response. An alternative approach is the addition of immunomodulator (IM) therapy to
counteract the antibody response and regain efficacy of the biologic medication. The
investigators' goal is to treat patients' who have lost response to adalimumab or infliximab
with an immunomodulator with the goal of eliminating the circulating antibodies to the
anti-TNF and restoring efficacy.